Biggest News Aggregation in the World
๐Ÿ“ฐ Genmaba S News

Genmaba S News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Genmaba S. Real-time updates on events, politics, business and more.

Vestmark Advisory Solutions Inc. Buys 7,905 Shares of Genmab A/S (NASDAQ:GMAB)

Vestmark Advisory Solutions Inc. raised its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 28.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,656 shares of the company’s stock after buying an additional 7,905 shares during the period. Vestmark […]
City Of United Kingdom Vestmark Advisory Solutions Inc Northern Trust Corp Morgan Stanley Envestnet Asset Management Inc

Genmab A/S (GMAB) Scheduled to Post Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB – Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Genmab A/S has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call […]
Morgan Stanley Get Free Report Genmaba S Nasdaq Gmab
Source: wkrb13.com

Genmab A/S (NASDAQ:GMAB) Receives Average Recommendation of "Hold" from Analysts

Genmab A/S (NASDAQ:GMAB – Get Free Report) has been given a consensus rating of “Hold” by the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have issued a buy recommendation on […]
Jpmorgan Chase Co Advisor Group York Mellon Corp Dimensional Fund Advisors Genmabas Company Profile Blackrock Inc

FY2025 EPS Estimates for Genmab A/S Decreased by William Blair (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB – Free Report) – Investment analysts at William Blair dropped their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued to clients and investors on Wednesday, April 3rd. William Blair analyst M. Phipps now expects that the company will post earnings per share of $1.07 […]
William Blair Millennium Management Envestnet Asset Management Inc Morgan Stanley Macquarie Group Ltd Genmabas Company Profile

Genmab A/S (NASDAQ:GMAB) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB – Free Report) in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a $50.00 target price on the stock. Other equities analysts have also issued research reports about the company. Morgan Stanley reaffirmed an underweight rating on […]
China Universal Asset Management Co Ameriprise Financial Inc Sorce Advisory Morgan Stanley Geode Capital Management Free Report

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

In first major M&A, Genmab adding Profoundbio for $1.8B

Investors might not have been overly excited, but Genmab A/S executives enthused about the โ€œcomplementarityโ€ of its proposed acquisition of antibody-drug conjugate (ADC) specialist Profoundbio Inc. for $1.8 billion in cash. The deal, expected to close in the first half of 2024, marks the biggest by far for the Copenhagen, Denmark-based biopharma and the latest transaction for the red hot ADC space.
Profoundbio Inc Genmaba S Profoundbio Inc Deals Andm Amp A Antibody Drug Conjugate Rinatabart Sesutecan

Genmab A/S (NASDAQ:GMAB) Shares Gap Up to $29.30

Genmab A/S (NASDAQ:GMAB – Get Free Report)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $29.30, but opened at $30.32. Genmab A/S shares last traded at $30.41, with a volume of 35,398 shares traded. Analysts Set New Price Targets Several research analysts have recently weighed in […]
New York United States Headlands Technologies Pinnacle Bancorp Inc Morgan Stanley Securities Inc
Source: wkrb13.com

Genmab A/S (NASDAQ:GMAB) Earns "Buy" Rating from Truist Financial

Truist Financial restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB – Free Report) in a report released on Tuesday morning, Benzinga reports. Truist Financial currently has a $50.00 target price on the stock. GMAB has been the subject of several other reports. Citigroup lowered Genmab A/S from a neutral rating to a sell […]
Ameriprise Financial Inc China Universal Asset Management Co Geode Capital Management Sorce Advisory Truist Financial Free Report

Genmab A/S (NASDAQ:GMAB) Receives Average Rating of "Hold" from Analysts

Genmab A/S (NASDAQ:GMAB – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and eight have issued a buy recommendation on the company. The average […]
New York United States Headlands Technologies Pinnacle Bancorp Inc Securities Inc Genmabas Company Profile

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science